Thermo Fisher Scientific (NYSE:TMO) Price Target Raised to $775.00

Key Points

• Stifel Nicolaus raised Thermo Fisher Scientific’s price target from $650 to $775 and maintained a “buy” rating, implying 11.67% upside from the stock’s reported $693.98 price.
• Analyst sentiment is broadly positive, with a consensus “Moderate Buy” rating and an average price target of $670.29, although targets from several firms now reach $730–$775.
• Thermo Fisher exceeded quarterly expectations, reporting $6.68 in EPS and $12.14 billion in revenue, with revenue up 9.1% year over year; however, insiders sold $44.1 million of stock over the past three months.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) had its price target lifted by stock analysts at Stifel Nicolaus from $650.00 to $775.00 in a research report issued on Thursday, Benzinga reports. The firm presently has a "buy" rating on the medical research company's stock. Stifel Nicolaus' target price indicates a potential upside of 11.67% from the company's current price.

A number of other analysts have also recently commented on the company. Guggenheim started coverage on Thermo Fisher Scientific in a research report on Thursday, October 15th. They set a "buy" rating for the company. Deutsche Bank Aktiengesellschaft restated a "buy" rating and issued a $720.00 target price on shares of Thermo Fisher Scientific in a report on Friday, September 25th. Morgan Stanley raised their price target on shares of Thermo Fisher Scientific from $650.00 to $730.00 and gave the stock an "overweight" rating in a research note on Monday, October 12th. Barclays set a $775.00 price target on shares of Thermo Fisher Scientific in a report on Thursday. Finally, UBS Group raised shares of Thermo Fisher Scientific from a "neutral" rating to a "buy" rating and boosted their price objective for the company from $540.00 to $730.00 in a research report on Tuesday, September 8th. Two research analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating, three have assigned a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $670.29.

Thermo Fisher Scientific Price Performance

TMO stock opened at $693.98 on Thursday. The stock's 50 day moving average price is $642.42 and its 200 day moving average price is $552.67. The firm has a market cap of $256.60 billion, a P/E ratio of 37.33, a PEG ratio of 2.87 and a beta of 0.87. The company has a debt-to-equity ratio of 0.74, a quick ratio of 1.18 and a current ratio of 1.55. Thermo Fisher Scientific has a 1 year low of $435.27 and a 1 year high of $705.79.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its quarterly earnings results on Wednesday, October 21st. The medical research company reported $6.68 earnings per share for the quarter, topping the consensus estimate of $6.40 by $0.28. Thermo Fisher Scientific had a return on equity of 17.09% and a net margin of 15.04%. The company had revenue of $12.14 billion during the quarter, compared to the consensus estimate of $11.95 billion. During the same quarter last year, the business posted $5.79 earnings per share. Thermo Fisher Scientific's revenue was up 9.1% compared to the same quarter last year. On average, sell-side analysts expect that Thermo Fisher Scientific will post 25.13 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 275 shares of the firm's stock in a transaction dated Monday, August 24th. The stock was sold at an average price of $627.05, for a total value of $172,438.75. Following the sale, the chief executive officer directly owned 123,925 shares of the company's stock, valued at approximately $77,707,171.25. This trade represents a 0.22% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Lisa P. Britt sold 11,440 shares of the firm's stock in a transaction dated Wednesday, August 19th. The stock was sold at an average price of $613.12, for a total value of $7,014,092.80. Following the completion of the sale, the vice president directly owned 14,784 shares in the company, valued at approximately $9,064,366.08. The trade was a 43.62% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 73,768 shares of company stock worth $44,122,820 in the last three months. Company insiders own 0.33% of the company's stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Strengthening Families & Communities LLC increased its position in Thermo Fisher Scientific by 0.4% in the third quarter. Strengthening Families & Communities LLC now owns 4,721 shares of the medical research company's stock worth $3,187,000 after buying an additional 21 shares during the period. Bell Bank boosted its holdings in shares of Thermo Fisher Scientific by 10.8% during the third quarter. Bell Bank now owns 624 shares of the medical research company's stock valued at $421,000 after acquiring an additional 61 shares during the period. 55 North Private Wealth LLC grew its position in shares of Thermo Fisher Scientific by 40.9% during the third quarter. 55 North Private Wealth LLC now owns 906 shares of the medical research company's stock worth $612,000 after acquiring an additional 263 shares during the last quarter. Jeppson Wealth Management LLC bought a new position in shares of Thermo Fisher Scientific during the third quarter worth about $213,000. Finally, James Hambro & Partners LLP increased its holdings in shares of Thermo Fisher Scientific by 0.8% in the 3rd quarter. James Hambro & Partners LLP now owns 231,390 shares of the medical research company's stock worth $156,260,000 after acquiring an additional 1,919 shares during the period. Institutional investors and hedge funds own 89.23% of the company's stock.

More Thermo Fisher Scientific News

Here are the key news stories impacting Thermo Fisher Scientific this week:

• Positive Sentiment: Quarterly results exceeded expectations: Q3 revenue rose 9.1% year over year to $12.14 billion, while adjusted EPS increased 15% to $6.68, beating consensus estimates of $11.95 billion and $6.40, respectively. Thermo Fisher Scientific Reports Third Quarter 2026 Results
• Positive Sentiment: Growth broadened across key end markets: Organic revenue growth reached 6%, supported by pharmaceutical demand, clinical research, bioproduction and electron microscopy. Management also highlighted continued customer activity, AI integration and signs of recovery in previously weaker markets. TMO Q3 deep dive
• Positive Sentiment: Profitability and outlook improved: Operating margin reached 24.5%, aided by portfolio actions and productivity initiatives. Thermo Fisher raised its full-year 2026 revenue and earnings outlook, including a 4% organic revenue-growth target. Three key takeaways
• Positive Sentiment: Analyst confidence increased: Robert W. Baird raised its price target from $723 to $756 and upgraded or reaffirmed an “outperform” rating, implying additional upside from the current trading level.
• Neutral Sentiment: Investors delivered a measured response: Despite the earnings beat and higher guidance, the stock’s reaction has been relatively restrained, suggesting that strong results may have been partly anticipated and that valuation remains an important consideration. Q3 earnings disconnect
• Negative Sentiment: Short-term caution remains: Early trading included selling pressure following the report, and put-option purchases rose about 52% above average volume, indicating that some investors are hedging against volatility or disappointment after the earnings release.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc is a global supplier of laboratory products, analytical instruments, reagents, consumables, software and services used in scientific research, healthcare, pharmaceuticals, biotechnology and industrial applications. The company serves customers ranging from academic institutions and government agencies to hospitals, clinical laboratories and pharmaceutical manufacturers.

Its offerings include instruments and systems for genetic analysis, mass spectrometry, chromatography, electron microscopy and materials science, as well as molecular biology reagents, cell culture products, laboratory plastics and research chemicals.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.